Lead Investigator: Franziska Michor, Dana Farber Cancer Institute
Title of Proposal Research: Large-scale public data reuse to model immunotherapy response and resistance
Vivli Data Request: 7283
Funding Source: The research was supported by the Partnership for Accelerating Cancer Therapies (PACT) by Foundation of National Institute of Health
Potential Conflicts of Interest: None
Summary of the Proposed Research:
Immune Checkpoint Blockade (ICB) have provided significant clinical benefits. However, only few patients show positive response to the ICB treatment. We have previously developed a biomarker named TIDE to predict response using gene expression data. The TIDE score is reflecting accurate patient response in many cancer types. Now, we are continuously integrating more ICB clinical trial data to our TIDE database, which will be used to studying and evaluating more biomarker that can benefit the ICB patients and cancer immunology.
EGAS00001004545 EGAS00001004548 EGAD00001006282 EGAD00001006284
Data Contributor: Bristol Myers Squibb
Study ID: CA209-038
Sponsor ID: CA209-038
Update: This data request was withdrawn on 22-Aug-2022 by the researcher.